Free Trial

ICON (ICLR) Competitors

ICON logo
$150.82 +1.94 (+1.30%)
Closing price 04:00 PM Eastern
Extended Trading
$150.52 -0.29 (-0.20%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICLR vs. MEDP, CRL, IQV, TCOM, RDDT, GIB, CPAY, TOST, AER, and GRAB

Should you be buying ICON stock or one of its competitors? The main competitors of ICON include Medpace (MEDP), Charles River Laboratories International (CRL), IQVIA (IQV), Trip.com Group (TCOM), Reddit (RDDT), CGI Group (GIB), Corpay (CPAY), Toast (TOST), Aercap (AER), and Grab (GRAB).

ICON vs. Its Competitors

ICON (NASDAQ:ICLR) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

95.6% of ICON shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 44.0% of ICON shares are held by insiders. Comparatively, 20.3% of Medpace shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ICON currently has a consensus price target of $213.08, suggesting a potential upside of 41.28%. Medpace has a consensus price target of $344.82, suggesting a potential upside of 5.76%. Given ICON's stronger consensus rating and higher possible upside, analysts clearly believe ICON is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ICON
0 Sell rating(s)
7 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.60
Medpace
0 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.21

In the previous week, ICON had 1 more articles in the media than Medpace. MarketBeat recorded 7 mentions for ICON and 6 mentions for Medpace. Medpace's average media sentiment score of 0.82 beat ICON's score of 0.65 indicating that Medpace is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ICON
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Medpace
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ICON has higher revenue and earnings than Medpace. ICON is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICON$8.28B1.47$791.47M$9.1816.43
Medpace$2.11B4.44$404.39M$13.1024.89

ICON has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Medpace has a net margin of 19.31% compared to ICON's net margin of 9.25%. Medpace's return on equity of 54.36% beat ICON's return on equity.

Company Net Margins Return on Equity Return on Assets
ICON9.25% 11.46% 6.49%
Medpace 19.31%54.36%20.81%

Summary

ICON beats Medpace on 9 of the 17 factors compared between the two stocks.

Get ICON News Delivered to You Automatically

Sign up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ICLR vs. The Competition

MetricICONMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$12.02B$7.29B$5.49B$8.93B
Dividend YieldN/A2.79%5.38%4.13%
P/E Ratio16.4328.1026.2119.90
Price / Sales1.4732.00405.84161.31
Price / Cash7.4322.0136.4957.06
Price / Book1.286.628.055.38
Net Income$791.47M$230.16M$3.15B$248.50M
7 Day Performance3.37%3.57%1.85%2.97%
1 Month Performance17.01%5.73%4.81%6.02%
1 Year Performance-52.62%33.35%34.86%20.39%

ICON Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICLR
ICON
4.3963 of 5 stars
$150.82
+1.3%
$213.08
+41.3%
-53.0%$12.02B$8.28B16.4341,900
MEDP
Medpace
4.4543 of 5 stars
$313.86
+1.0%
$344.82
+9.9%
-21.2%$9.02B$2.16B23.965,900
CRL
Charles River Laboratories International
4.0308 of 5 stars
$151.64
+1.1%
$171.85
+13.3%
-23.8%$7.45B$4.05B-233.2920,100Positive News
IQV
IQVIA
4.8807 of 5 stars
$157.69
+0.1%
$226.32
+43.5%
-22.0%$27.28B$15.41B21.4886,000Positive News
TCOM
Trip.com Group
4.8962 of 5 stars
$58.64
-0.1%
$77.25
+31.7%
+24.0%$38.31B$7.30B17.0033,700
RDDT
Reddit
2.1888 of 5 stars
$150.74
+5.4%
$139.57
-7.4%
+129.1%$27.81B$1.30B255.502,233Trending News
Analyst Forecast
GIB
CGI Group
3.8702 of 5 stars
$104.93
+1.5%
$156.75
+49.4%
+6.8%$23.55B$10.79B19.1190,000Positive News
CPAY
Corpay
3.9246 of 5 stars
$332.07
+1.5%
$401.86
+21.0%
+27.3%$23.41B$3.97B23.2910,500Positive News
Analyst Upgrade
TOST
Toast
2.8499 of 5 stars
$44.33
+1.0%
$41.21
-7.0%
+69.2%$22.08B$4.96B192.744,500
AER
Aercap
2.5711 of 5 stars
$116.96
-0.2%
$119.25
+2.0%
+25.0%$21.85B$8.06B10.38740Positive News
GRAB
Grab
1.7479 of 5 stars
$5.03
+2.2%
$5.71
+13.4%
+39.7%$20.26B$2.80B251.639,490Trending News

Related Companies and Tools


This page (NASDAQ:ICLR) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners